by Don Cross | Oct 3, 2020 | News, Uncategorized
Tau predicted early disability and worse prognosis in multiple sclerosis (MS) patients independently of age, a longitudinal prospective study showed. MS patients with higher cerebrospinal fluid (CSF) tau levels at diagnosis developed higher MS Severity Scores (MSSS)...
by Don Cross | Sep 29, 2020 | News, Uncategorized
Masitinib, an orally administered tyrosine kinase inhibitor targeting the innate immune system, showed positive signs in treating progressive forms of multiple sclerosis (MS) in the phase III AB07002 trial. The drug, which specifically downregulates mast cells and...
by Don Cross | Sep 29, 2020 | News, Uncategorized
Serum neurofilament light (NfL) levels rose in women with multiple sclerosis (MS) during pregnancy and postpartum periods when no disease-modifying treatment (DMT) was used, researchers reported. This rise in NfL, a measure of axonal injury, was independent of MS...
by Don Cross | Sep 22, 2020 | News, Uncategorized
The effort to individualize MS care to optimal effect for each patient has been greatly enhanced in recent years by the identification of distinct phenotypes, or forms, of multiple sclerosis that have different clinical courses and responses to disease-modifying...
by Don Cross | Sep 22, 2020 | News, Uncategorized
It long has been known that women are at an increased risk for MS relative to men, but a recent study now raises the prospect that a woman’s childbearing status may affect her risk for earlier onset of progressive multiple sclerosis. [Zeydan 2020] A group of...
by Don Cross | Sep 11, 2020 | News, Uncategorized
The MSAV depends on the generous support of people like you to continue its mission. To participate in one of our fundraising events online or to shop online with a small portion of your purchase going to support the MSAV, click one of the links below: Kroger Did you...
